Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

An interactive web-based dashboard to track COVID-19 in real time

Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048 · see citing works

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266 · see citing works

Factors associated with COVID-19-related death using OpenSAFELY

Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674 · see citing works

Virological assessment of hospitalized patients with COVID-2019

Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661 · see citing works

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · see citing works

Temporal dynamics in viral shedding and transmissibility of COVID-19

He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,242 · see citing works

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., Zimmer, T., Thiel, V., Jänke, C., Guggemos, W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001468 · Cited by 4,143 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Nextstrain: real-time tracking of pathogen evolution

Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154 · see citing works

Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche

Kärber, G. (1931) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf01863914 · Cited by 3,074 · see citing works

Antibody responses to SARS-CoV-2 in patients with COVID-19

Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · see citing works

ggeffects: Tidy Data Frames of Marginal Effects from Regression Models

Lüdecke, D. (2018) · The Journal of Open Source Software · doi:10.21105/joss.00772 · Cited by 2,742 · see citing works

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · see citing works

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,633 · cited 1× · see citing works

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557 · see citing works

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · see citing works

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works

Prevalence of Asymptomatic SARS-CoV-2 Infection

Oran, D. P., & Topol, E. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3012 · Cited by 2,280 · see citing works

SARS-CoV-2 vaccines in development

Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · see citing works

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · see citing works

Data, disease and diplomacy: GISAID's innovative contribution to global health

Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928 · see citing works

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · see citing works

Learning Bayesian Networks with the bnlearn R Package

Scutari, M. (2010) · Journal of Statistical Software · doi:10.18637/jss.v035.i03 · Cited by 1,798 · see citing works

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790 · see citing works

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642 · see citing works

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395 · see citing works

Duration of Humoral Immunity to Common Viral and Vaccine Antigens

Amanna, I. J., Carlson, N. E., & Slifka, M. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066092 · Cited by 1,286 · see citing works

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282 · see citing works

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · see citing works

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195 · see citing works

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ni, L., Ye, F., Cheng, M., Yu, F., Deng, Y., Zhao, H. J., Peng, W., Ge, J., Gou, M., Li, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.023 · Cited by 1,069 · see citing works

Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques

McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068 · see citing works

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026 · see citing works

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · see citing works

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works

Seasonal coronavirus protective immunity is short-lasting

Edridge, A. W. D., Kaczorowska, J., Hoste, A. C. R., Bakker, M., Klein, M., Loens, K., Jebbink, M. F., Matser, A., Kinsella, C. M., Rueda, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1083-1 · Cited by 767 · see citing works

Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications

Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754 · see citing works

THE METHOD OF ‘RIGHT AND WRONG CASES’ (‘CONSTANT STIMULI’) WITHOUT GAUSS'S FORMULAE

Spearman, C. (1908) · British Journal of Psychology 1904-1920 · doi:10.1111/j.2044-8295.1908.tb00176.x · Cited by 745 · see citing works

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 727 · see citing works

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722 · see citing works

Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study

Augustin, M., Schommers, P., Stecher, M., Dewald, F., Gieselmann, L., Gruell, H., Horn, C., Vanshylla, K., Cristanziano, V. D., Osebold, L., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100122 · Cited by 685 · see citing works

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Iyer, A., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M. V., Slater, D., Mills, R., Teng, E., Kamruzzaman, M., Garcia-Beltran, W., et al. (2020) · Science immunology · doi:10.1126/sciimmunol.abe0367 · Cited by 612 · see citing works

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606 · see citing works

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

Simek, M. D., RIDA, W. N., Priddy, F. H., Pung, P., Carrow, E. W., Laufer, D. S., Lehrman, J. K., Boaz, M. J., Tarragona-Fiol, T., Miiro, G., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00110-09 · Cited by 594 · see citing works

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508 · see citing works

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1555 · Cited by 475 · see citing works

Broadly Neutralizing Antiviral Antibodies

Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 469 · see citing works

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Röltgen, K., Powell, A. E., Wirz, O. F., Stevens, B. A., Hogan, C. A., Najeeb, J., Hunter, M., Wang, H., Sahoo, M. K., Huang, C., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe0240 · Cited by 452 · see citing works

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 423 · see citing works

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery

Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367 · see citing works

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Lv, Z., Deng, Y., Ye, Q., Cao, L., Sun, C.-Y., Fan, C., Huang, W., Sun, S., Sun, Y., Zhu, L., et al. (2020) · Science · doi:10.1126/science.abc5881 · Cited by 362 · see citing works

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.012 · Cited by 324 · see citing works

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Kreer, C., Zehner, M., Weber, T., Ercanoglu, M. S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.044 · Cited by 313 · see citing works

Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray

Walker, L., & Burton, D. (2018) · Nature reviews. Immunology · doi:10.1038/nri.2017.148 · Cited by 242 · see citing works

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

Chen, X., Pan, Z., Yue, S., Yu, F., Zhang, J., Yang, Y., Li, R., Liu, B., Yang, X., Gao, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00301-9 · Cited by 234 · see citing works

Dissecting antibody-mediated protection against SARS-CoV-2

Zohar, T., & Alter, G. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0359-5 · Cited by 231 · see citing works

Antibody responses to viral infections: a structural perspective across three different enveloped viruses

Murin, C. D., Wilson, I. A., & Ward, A. B. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0392-y · Cited by 210 · see citing works

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100126 · Cited by 197 · see citing works

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients

Luchsinger, L. L., Ransegnola, B. P., Jin, D. K., Muecksch, F., Weisblum, Y., Bao, W., George, P. J., Rodriguez, M., Tricoche, N., Schmidt, F., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02005-20 · Cited by 187 · see citing works

Longitudinal symptom dynamics of COVID-19 infection

Mizrahi, B., Shilo, S., Rossman, H., Kalkstein, N., Marcus, K., Barer, Y., Keshet, A., Shamir-Stein, N., Shalev, V., Zohar, A. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20053-y · Cited by 187 · see citing works

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2021) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2103154118 · Cited by 187 · see citing works

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

Ng, D. L., Goldgof, G. M., Shy, B. R., Levine, A. G., Balcerek, J., Bapat, S. P., Prostko, J. C., Rodgers, M. A., Coller, K. E., Pearce, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18468-8 · Cited by 185 · see citing works

Long-term COVID-19 symptoms in a large unselected populationPreprint

Cirulli, E. T., Barrett, K. M. S., Riffle, S., Bolze, A., Neveux, I., Dabe, S., Grzymski, J. J., Lu, J. T., & Washington, N. L. (2020) · medRxiv · doi:10.1101/2020.10.07.20208702 · Cited by 172 · see citing works

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2

Klingler, J., Weiß, S., Itri, V., Liu, X., Oguntuyo, K. Y., Stevens, C. S., Ikegame, S., Hung, C.-T., Enyindah-Asonye, G. M., Amanat, F., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa784 · Cited by 127 · see citing works

The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunityPreprint

Thomson, E., Rosen, L. E., Shepherd, J., et al. (2020) · bioRxiv · doi:10.1101/2020.11.04.355842 · Cited by 104 · see citing works

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors

Zeng, C., Evans, J. P., Pearson, R., Qu, P., Zheng, Y.-M., Robinson, R., Hall‐Stoodley, L., Yount, J. S., Pannu, S. R., Mallampalli, R. K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143213 · Cited by 87 · see citing works

Role of IgM and IgA Antibodies to the Neutralization of SARS-CoV-2Preprint

Klingler, J., Weiß, S., Itri, V., et al. (2020) · medRxiv · doi:10.1101/2020.08.18.20177303 · Cited by 74 · see citing works

Persistence of COVID-19 Symptoms after Recovery in Mexican Population

Galvan-Tejada, C. E., Herrera-García, C. F., Godina-González, S., Villagrana-Bañuelos, K. E., Amaro, J. D. D. L., Herrera-García, K., Rodríguez-Quiñones, C., Zanella-Calzada, L. A., Ramírez-Barranco, J., de Avila, J. L. R., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249367 · Cited by 67 · see citing works

Antibody-guided vaccine design: identification of protective epitopes

Lanzavecchia, A., Frühwirth, A., Perez, L. H., & Corti, D. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.001 · Cited by 60 · see citing works

COVID-19 neutralizing antibodies predict disease severity and survival

Garcia-Beltran, W., Lam, E., Astudillo, M., Yang, D., Miller, T., Feldman, J., Hauser, B., Caradonna, T. M., Clayton, K., Nitido, A. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.015 · Cited by 56 · see citing works

Recovered not restored: Long-term health consequences after mild COVID-19 in non-hospitalized patientsPreprint

Augustin, M., Schommers, P., Stecher, M., et al. (2021) · medRxiv · doi:10.1101/2021.03.11.21253207 · Cited by 7 · see citing works

SARS-CoV-2 escape <i>in vitro</i> from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020) · doi:10.1101/2020.12.28.424451

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703 · see citing works

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410 · see citing works

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Hillus, D., Schwarz, T., Tober‐Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 343 · see citing works

Immunity to SARS‐CoV‐2 induced by infection or vaccination

Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 164 · see citing works

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei, J., Matthews, P. C., Stoesser, N. E., Maddox, T., Lorenzi, L., Studley, R., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26479-2 · Cited by 131 · see citing works

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

Keeton, R. S., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 105 · see citing works

Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

Yang, Y., Yang, M.-H., Peng, Y., Liang, Y.-J., Wei, J.-L., Xing, L., Guo, L., Li, X.-H., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 104 · see citing works

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Dupont, L., Snell, L., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 98 · see citing works

The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?

Boyton, R. J., & Altmann, D. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00631-x · Cited by 98 · see citing works

Point-of-care diagnostics: recent developments in a pandemic age

Harpaldas, H., Arumugam, S., Rodriguez, C. C., Kumar, B. A., Shi, V. Y., & Sia, S. K. (2021) · Lab on a Chip · doi:10.1039/d1lc00627d · Cited by 82 · see citing works

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns

Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.002 · Cited by 75 · see citing works

Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · doi:10.1101/2021.08.26.21262468 · Cited by 69 · see citing works

Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?

van den Hoogen, L. L., Smits, G. P., van Hagen, C. C. E., Wong, D., Vos, E. R. A., van Boven, M., de Melker, H. E., van Vliet, J., Kuijer, M., Woudstra, L., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.009 · Cited by 63 · see citing works

Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers

Vanshylla, K., Fan, C., Wunsch, M., Poopalasingam, N., Meijers, M., Kreer, C., Kleipass, F., Ruchnewitz, D., Ercanoglu, M. S., Gruell, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.010 · Cited by 55 · see citing works

Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses

Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 58 · see citing works

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Halwe, S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M., Rohde, C., Krähling, V., Serra, M. G., Kreer, C., et al. (2021) · Viruses · doi:10.3390/v13081498 · Cited by 53 · see citing works

The way of SARS-CoV-2 vaccine development: success and challenges

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53 · see citing works

Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection

Wang, H., Yuan, Y. L., Xiao, M., Chen, L., Zhao, Y., Zhang, H., Long, P., Zhou, Y., Xu, X. Z., Lei, Y., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00708-6 · Cited by 52 · see citing works

Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters

Burckhardt, R. M., Dennehy, J. J., Poon, L. L. M., Saif, L. J., & Enquist, L. W. (2021) · Journal of Virology · doi:10.1128/jvi.01973-21 · Cited by 50 · see citing works

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

Fabricius, D., Ludwig, C., Scholz, J. A. M., Rode, I., Tsamadou, C., Jacobsen, E., Winkelmann, M., Grempels, A., Lotfi, R., Janda, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080918 · Cited by 44 · see citing works

Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection

Wright, P. F., Prevost-Reilly, A., Natarajan, H., Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Miele, A. S., Weiner, J. A., Nerenz, R. D., & Ackerman, M. E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac065 · Cited by 44 · see citing works

Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion

Eser, T. M., Baranov, O., Huth, M., Ahmed, M. I. M., Deák, F., Held, K., Lin, L., Pekayvaz, K., Leunig, A., Nicolai, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38020-8 · Cited by 37 · see citing works

Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden

Dopico, X. C., Muschiol, S., Christian, M., Hanke, L., Sheward, D. J., Grinberg, N. F., Rorbach, J., Bogdanović, G., McInerney, G. M., Allander, T., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13304 · Cited by 36 · see citing works

mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants

Yu, Y., Esposito, D., Kang, Z., Lü, J., Remaley, A. T., Giorgi, V. D., Chen, L. N., West, K. A., & Cao, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-06629-2 · Cited by 38 · see citing works

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study

Singh, A. K., Phatak, S., Singh, R., Bhattacharjee, K., Singh, N. K., Gupta, A., & Sharma, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102424 · Cited by 38 · see citing works

Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool

Weber, T., Dähling, S., Rose, S., Affeldt, P., Vanshylla, K., Ullrich, L., Gieselmann, L., Teipel, F., Gruell, H., Cristanziano, V. D., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adk5845 · Cited by 38 · see citing works

Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020

Wagner, R., Peterhoff, D., Beileke, S., Günther, F., Berr, M., Einhauser, S., Schütz, A., Niller, H. H., Steininger, P. A., Knöll, A., et al. (2021) · Viruses · doi:10.3390/v13061118 · Cited by 38 · see citing works

Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein

de Castro, J. T., de Azevedo, P. O., Fumagalli, M. J., Hojo-Souza, N. S., Salazar, N., Almeida, G. G., Oliveira, L. I., Faustino, L., Antonelli, L. R. D. V., Marçal, T. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32547-y · Cited by 36 · see citing works

Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel

Glück, V., Grobecker, S., Köstler, J., Tydykov, L., Bertok, M., Weidlich, T., Gottwald, C., Salzberger, B., Wagner, R., Zeman, F., et al. (2021) · Infection · doi:10.1007/s15010-021-01703-9 · Cited by 34 · see citing works

B lymphocytes in COVID-19: a tale of harmony and discordance

Mansourabadi, A. H., Aghamajidi, A., Dorfaki, M., Keshavarz, F., Shafeghat, Z., Moazzeni, A., Arab, F. L., Rajabian, A., Roozbehani, M., Falak, R., et al. (2023) · Archives of Virology · doi:10.1007/s00705-023-05773-y · Cited by 33 · see citing works

Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants

Korenkov, M., Zehner, M., Cohen‐Dvashi, H., Borenstein-Katz, A., Kottege, L., Janicki, H., Vanshylla, K., Weber, T., Gruell, H., Koch, M., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.004 · Cited by 34 · see citing works

Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort

Menges, D., Zens, K. D., Ballouz, T., Caduff, N., Llanas-Cornejo, D., Aschmann, H. E., Domenghino, A., Pellaton, C., Perreau, M., Fenwick, C. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32573-w · Cited by 31 · see citing works

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod

Meyer‐Arndt, L., Braun, J., Fauchère, F., Vanshylla, K., Loyal, L., Henze, L., Kruse, B., Dingeldey, M., Jürchott, K., Mangold, M., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329395 · Cited by 31 · see citing works

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response

Takamatsu, Y., Omata, K., Shimizu, Y., Kinoshita, N., Terada, M., Suzuki, T., Morioka, S., Uemura, Y., Ohmagari, N., Maeda, K., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02716-22 · Cited by 31 · see citing works

Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months

Robertson, L. J., Moore, J. S., Blighe, K., Ng, K. Y., Quinn, N., Jennings, F., Warnock, G., Sharpe, P. C., Clarke, M., Maguire, K., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048142 · Cited by 31 · see citing works

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

zu Natrup, C. M., Tscherne, A., Dahlke, C., Ciurkiewicz, M., Shin, D., Fathi, A., Rohde, C., Kalodimou, G., Halwe, S., Limpinsel, L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159895 · Cited by 31 · see citing works

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Tarrés-Freixas, F., Ortiz, R., Rovirosa, C., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100523 · Cited by 28 · see citing works

Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults

Rennert, L., Ma, Z., McMahan, C. S., & Dean, D. M. D. (2022) · Nature Communications · doi:10.1038/s41467-022-31469-z · Cited by 30 · see citing works

Structural Immunology of SARS ‐ CoV ‐2

Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 28 · see citing works

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

Eberhardt, K. A., Dewald, F., Heger, E., Gieselmann, L., Vanshylla, K., Wirtz, M., Kleipass, F., Johannis, W., Schommers, P., Gruell, H., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040733 · Cited by 25 · see citing works

Evaluation of Clove Phytochemicals as Potential Antiviral Drug Candidates Targeting SARS-CoV-2 Main Protease: Computational Docking, Molecular Dynamics Simulation, and Pharmacokinetic Profiling

Manivannan, A. C., Malaisamy, A., Eswaran, M., Meyyazhagan, A., Arumugam, V. A., Rengasamy, K. R. R., Balasubramanian, B., & Liu, W. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.918101 · Cited by 27 · see citing works

Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection

Perez‐Saez, J., Zaballa, M.-E., Lamour, J., Yerly, S., Dubos, R., Courvoisier, D. S., Villers, J., Balavoine, J.-F., Pittet, D., Kherad, O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38744-7 · Cited by 22 · see citing works

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 21 · see citing works

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals

Hirotsu, Y., Amemiya, K., Sugiura, H., Shinohara, M., Takatori, M., Mochizuki, H., & Omata, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722766 · Cited by 22 · see citing works

A comprehensive assessment of long-term SARS-CoV-2–specific adaptive immune memory in convalescent COVID-19 Solid Organ Transplant recipients

Favà, A., Donadeu, L., Jouvé, T., González‐Costello, J., Lladó, L., Santana, C., Toapanta, N., Comabella, M., Pernin, V., Facundo, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2021.12.029 · Cited by 21 · see citing works

Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors

Barnes, T. W., Schulte-Pelkum, J., Steller, L., Filchtinski, D., Jenness, R., Williams, M. R., Kober, C., Manni, S., Hauser, T., Hahn, A., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108871 · Cited by 19 · see citing works

Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset

Law, J. C., Girard, M., Chao, G. Y. C., Ward, L. A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J. M., Yue, F. Y., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100727 · Cited by 21 · see citing works

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection

Alexandre, M., Marlin, R., Prague, M., Coléon, S., Kahlaoui, N., Cardinaud, S., Naninck, T., Delache, B., Surenaud, M., Galhaut, M., et al. (2022) · eLife · doi:10.7554/elife.75427 · Cited by 17 · see citing works

Pre-existing neutralizing antibodies against cattle-transmitted influenza A virus H5N1 are detectable in unexposed individuals

Daniel, K., Ullrich, L., Ruchnewitz, D., Meijers, M., Halwe, N. J., Wild, U., Eberhardt, J., Schön, J., Stumpf, R., Schlotz, M., et al. (2026) · Immunity · doi:10.1016/j.immuni.2025.12.013 · Cited by 17 · see citing works

Factors influencing the immune response over 15 months after SARS‐CoV‐2 infection: A longitudinal population‐wide study in the Faroe Islands

Petersen, M. S., Pérez‐Alós, L., Armenteros, J. J. A., Hansen, C. B., Fjallsbak, J. P., Larsen, S., Hansen, J. L., Jarlhelt, I., Kristiansen, M. F., Streym, F. V., et al. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13560 · Cited by 18 · see citing works

Dynamics and durability of HIV-1 neutralization are determined by viral replication

Schommers, P., Kim, D. S., Schlotz, M., Kreer, C., Eggeling, R., Hake, A., Stecher, M., Park, J., Radford, C. E., Dingens, A. S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02582-3 · Cited by 15 · see citing works

Cohort profile: Stop the Spread Ottawa (SSO)—a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination

Collins, E., Galipeau, Y., Arnold, C., Bosveld, C., Heiskanen, A., Keeshan, A., Nakka, K., Shir-Mohammadi, K., St-Denis-Bissonnette, F., Tamblyn, L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062187 · Cited by 14 · see citing works

Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study

Owusu‐Boaitey, N., Russell, T., Meyerowitz‐Katz, G., Levin, A., & Herrera, D. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.21.2200809 · Cited by 16 · see citing works

Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine primingPreprint

Zhang, Z., Wu, S., Liu, Y., Li, K., Fan, P., Song, X., Wang, Y., Zhao, Z., Zhang, X., Shang, J., et al. (2022) · medRxiv · doi:10.1101/2022.03.08.22271816 · Cited by 16 · see citing works

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose

Mangia, A., Serra, N., Cocomazzi, G., Giambra, V., Antinucci, S., Maiorana, A., Giuliani, F., Montomoli, E., Cantaloni, P., Manenti, A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.847384 · Cited by 15 · see citing works

Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients

Takeshita, M., Nishina, N., Moriyama, S., Takahashi, Y., Ishii, M., Saya, H., Kondo, Y., Kaneko, Y., Suzuki, K., Fukunaga, K., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108999 · Cited by 12 · see citing works

Development and Implementation of Dried Blood Spot-Based COVID-19 Serological Assays for Epidemiologic Studies

Wong, M. P., Meas, M., Adams, C., Hernandez, S., Green, V., Montoya, M., Hirsch, B. M., Horton, M. K., Quach, H., Quach, D. L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02471-21 · Cited by 14 · see citing works

Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms

Carreño, J. M., Mendu, D. R., Simon, V. R., Shariff, M. A., Singh, G., Menon, V. P., & Krammer, F. (2021) · iScience · doi:10.1016/j.isci.2021.102937 · Cited by 12 · see citing works

Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines

Sepand, M. R., Bigdelou, B., Ho, J. Q., Sharaf, M., Lannigan, A. J., Sullivan, I. M., da Silva, A. P., Barrett, L. O., McGoldrick, S., Lnu, Y., et al. (2022) · Antibodies · doi:10.3390/antib11020035 · Cited by 13 · see citing works

A unique cytotoxic CD4 + T cell‐signature defines critical COVID‐19

Baird, S., Ashley, C. L., Marsh‐Wakefield, F., Alca, S., Ashhurst, T. M., Ferguson, A. L., Lukeman, H., Counoupas, C., Post, J. J., Koneçny, P., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1463 · Cited by 13 · see citing works

Blood and saliva SARS-CoV-2 antibody levels in self-collected dried spot samples

Lahdentausta, L., Kivimäki, A. S., Oksanen, L., Tallgren, M., Oksanen, S. A., Sanmark, E., Salminen, A., Geneid, A., Sairanen, M., Paju, S., et al. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00740-x · Cited by 13 · see citing works

Delineating antibody escape from Omicron sublineagesPreprint

Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487257 · Cited by 13 · see citing works

Recurrent SARS-CoV-2 infections and their potential risk to public health – a systematic review

Abrokwa, S. K., Müller, S. A., Méndez-Brito, A., Hanefeld, J., & Bcheraoui, C. E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261221 · Cited by 11 · see citing works

Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity

Kim, Y., Bae, J., Kwon, K. T., Chang, H., Lee, W. K., Park, H., Kim, J., Choi, I., Park, M., & Kim, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-17605-1 · Cited by 11 · see citing works

Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells

Krause, R. G. E., Moyo-Gwete, T., Richardson, S. I., Makhado, Z., Manamela, N. P., Hermanus, T., Mkhize, N. N., Keeton, R. S., Benede, N., Mennen, M., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00724-9 · Cited by 9 · see citing works

SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise

Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12 · see citing works

Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination

Urlaub, D., Wolfsdorff, N., Hoffmann, J., Dorok, S., Hoffmann, M., Anft, M., Pieris, N., Günther, P. S., Schaaf, B., Cassens, U., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149758 · Cited by 11 · see citing works

Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection

Wang, X., Zhang, M., Wei, K., Li, C., Yang, J., Jiang, S., Zhao, C., Zhao, X., Qiao, R., Cui, Y., et al. (2024) · Vaccines · doi:10.3390/vaccines12050464 · Cited by 10 · see citing works

Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches

Stinca, S., Barnes, T. W., Peter, V., Meyers, W., Schulte-Pelkum, J., Filchtinski, D., Steller, L., Hauser, T., Manni, S., Gardiner, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259731 · Cited by 10 · see citing works

No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults

Ercanoglu, M. S., Gieselmann, L., Dähling, S., Poopalasingam, N., Detmer, S., Koch, M., Korenkov, M., Halwe, S., Klüver, M., Cristanziano, V. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103951 · Cited by 9 · see citing works

Functional Characteristics of Serum Anti-SARS-CoV-2 Antibodies against Delta and Omicron Variants after Vaccination with Sputnik V

Radion, E. I., Mukhin, V. E., Kholodova, A. V., Vladimirov, I. S., Alsaeva, D. Y., Zhdanova, A. S., Ulasova, N. Y., Bulanova, N. V., Makarov, V. V., Keskinov, A. A., et al. (2023) · Viruses · doi:10.3390/v15061349 · Cited by 11 · see citing works

Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19–convalescent individuals

Min, L., Liu, J., Lu, R., Zhang, Y., Du, M., Xing, M., Wu, Z., Kong, X., Zhu, Y., Zhou, X., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.005 · Cited by 10 · see citing works

Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility

Lai, A., Caimi, B., Franzetti, M., Bergna, A., Velleca, R., Gatti, A., Rossi, P. L., D'Orso, M. I., Pregliasco, F. E., Balotta, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10030446 · Cited by 10 · see citing works

The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells

Bilgin, H., Marku, M., Yılmaz, S. S., Yağcı, A., Sili, U., Can, B., Sarınoğlu, R. C., Mülazımoğlu, L., Haklar, G., Şïrïkçï, Ö., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.001 · Cited by 10 · see citing works

Design, Development and Immunogenicity Study of a Multi-Epitope Vaccine Prototype Against SARS-CoV-2

Atanasova, M., Dimitrov, I., Ralchev, N., Markovski, A. M., Manoylov, I. K., Bradyanova, S. L., Mihaylova, N., Tchorbanov, A. I., & Doytchinova, I. A. (2024) · Pharmaceuticals · doi:10.3390/ph17111498 · Cited by 9 · see citing works

Bridging the gap - estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel

Harries, M., Jaeger, V. K., Rodiah, I., Hassenstein, M. J., Ortmann, J., Dreier, M., von Holt, I., Brinkmann, M., Dulovic, A., Gornyk, D., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.014 · Cited by 9 · see citing works

Knowledge, Attitudes, and Practices of Adult Iraqi Population Towards COVID-19 Booster Dose: A Cross-Sectional Study

Al-Qerem, W. A., Jarab, A. S., Hammad, A. M., Alsajri, A. H., Al-Hishma, S. W., Ling, J., Alabdullah, A. S., Salama, A., & Mosleh, R. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s370124 · Cited by 8 · see citing works

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity

Henze, L., Braun, J., Meyer‐Arndt, L., Jürchott, K., Schlotz, M., Michel, J., Grossegesse, M., Mangold, M., Dingeldey, M., Kruse, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1056525 · Cited by 7 · see citing works

Determination of the frequency of individuals with broadly cross-reactive neutralizing antibodies against PRRSV in the sow population under field conditions

Plaza-Soriano, Á., Martínez-Lobo, F. J., Garza‐Moreno, L., Castillo-Pérez, J., Caballero, E., Castro, J. M., Simarro, I., & Prieto, C. (2024) · Porcine Health Management · doi:10.1186/s40813-024-00372-y · Cited by 8 · see citing works

Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease

Stich, M., Cristanziano, V. D., Tönshoff, B., Weber, L. T., Dötsch, J., Rammer, M. T., Rieger, S., Heger, E., Garbade, S. F., Burgmaier, K., et al. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05806-9 · Cited by 8 · see citing works

Risk of waning humoral responses after inactivated or subunit recombinant SARS‐CoV‐2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China

Li, H., Cai, D., Jiang, D., Li, X., Liao, X., Liu, D., Liu, Z., Zhu, P., Yin, G., Ming, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28434 · Cited by 8 · see citing works

Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets

Zheng, Z., Li, X., Nie, K., Wang, X., Liang, W., Yang, F., Zheng, K., & Zheng, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1038651 · Cited by 8 · see citing works

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients

Dewald, F., Pirkl, M., Paluschinski, M., Kühn, J., Elsner, C., Schulte, B., Knüfer, J., Ahmadov, E., Schlotz, M., Oral, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38127-y · Cited by 9 · see citing works

Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use

Werner, M., Pervan, P., Glück, V., Zeman, F., Koller, M. T., Burkhardt, R., Glück, T., Wenzel, J. J., Schmidt, B., Gessner, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081580 · Cited by 8 · see citing works

Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients

Borgogna, C., Bruna, R., Griffante, G., Martuscelli, L., Andrea, M. D., Ferrante, D., Patriarca, A., Mahmoud, A. M., Gaidano, V., Marchetti, M., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00608-6 · Cited by 8 · see citing works

A prospective study of the impact of glycaemic status on clinical outcomes and anti-SARS-CoV-2 antibody responses among patients with predominantly non-severe COVID-19

Lui, D. T. W., Li, Y. K., Lee, C. H., Chow, W.-S., Lee, A. C. H., Tam, A. R., Pang, P., Ho, T. Y., Cheung, C. Y. Y., Fong, C. H.-Y., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109232 · Cited by 7 · see citing works

Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19

Mellinghoff, S. C., Vanshylla, K., Dahlke, C., Addo, M. M., Cornely, O. A., Klein, F., ten Persigehl, T., Rybniker, J., Gruell, H., & Bröckelmann, P. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798276 · Cited by 7 · see citing works

Exploring Factors Influencing Changes in Incidence and Severity of Multisystem Inflammatory Syndrome in Children

Castaldo, P., d’Alanno, G., Biserni, G. B., Moratti, M., Conti, F., Fabi, M., & Lanari, M. (2023) · Pathogens · doi:10.3390/pathogens12080997 · Cited by 7 · see citing works

Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling

Denani, C. B., Setatino, B. P., Pereira, D., Horbach, I. S., Azevedo, A. D. S., Coutinho, G., Ferroco, C. L. D. V., Xavier, J. R., Leite, R., dos Santos, E. A. P., et al. (2025) · Pathogens · doi:10.3390/pathogens14111129 · Cited by 7 · see citing works

Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19

Thibeault, C., Bardtke, L., Vanshylla, K., Cristanziano, V. D., Eberhardt, K. A., Stubbemann, P., Hillus, D., Tober‐Lau, P., Mukherjee, P., Münn, F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166711 · Cited by 6 · see citing works

Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study

Griffante, G., Chandel, S., Ferrante, D., Caneparo, V., Capello, D., Bettio, V., Borgogna, C., Aleni, C., Esposito, S., Sarro, A., et al. (2021) · Viruses · doi:10.3390/v13112270 · Cited by 6 · see citing works

The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2

Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5 · see citing works

Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment

Carlin, A. F., Clark, A. E., Garretson, A. F., Bray, W. A., Porrachia, M., Santos, A. T., Rana, T. M., Chaillon, A., & Smith, D. M. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad154 · Cited by 5 · see citing works

Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates

Dopico, X. C., Muschiol, S., Grinberg, N. F., Aleman, S., Sheward, D. J., Hanke, L., Ahl, M., Vikström, L., Forsell, M. N. E., Coquet, J. M., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1379 · Cited by 5 · see citing works

Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale

Viana, K. F., Zarpelon, L. F. B., Leandro, A., Terêncio, M. L., Lopes, R. D., Martins, C. A., Silva, I., Sibim, A. C., Marques, F., SILVA, R. D., et al. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001684 · Cited by 4 · see citing works

Long-Term Cross Immune Response in Mice following Heterologous Prime-Boost COVID-19 Vaccination with Full-Length Spike mRNA and Recombinant S1 Protein

Li, D., Zhao, H., Liao, Y., Jiang, G., Cui, P., Zhang, Y., Yu, L., Fan, S., Li, H., & Li, Q. (2023) · Vaccines · doi:10.3390/vaccines11050963 · Cited by 4 · see citing works

Population-based study of the durability of humoral immunity after SARS-CoV-2 infection

Peterhoff, D., Wiegrebe, S., Einhauser, S., Patt, A. J., Beileke, S., Günther, F., Steininger, P. A., Niller, H. H., Burkhardt, R., Küchenhoff, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242536 · Cited by 4 · see citing works

Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection

Викторович, К. С., Guselnikov, S. V., Nekrasov, B. G., Molodykh, S. V., Kuvshinova, I. N., Murasheva, S. V., Николаевна, Б. Т., Gorchakov, A. A., Chikaev, A. N., Chikaev, N. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12010055 · Cited by 4 · see citing works

Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka

Hoshida, S., Koeda, N., Hattori, H., Tanaka, M., Tanaka, I., Fukui, H., Fujita, J., Sasaki, Y., & Tamura, S. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07695-7 · Cited by 4 · see citing works

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2Preprint

Vanshylla, K., Cristanziano, V. D., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M., Stumpf, R., et al. (2021) · bioRxiv · doi:10.1101/2021.01.26.428207 · Cited by 129 · see citing works

Stable neutralizing-antibody levels 6 months after mild and severe COVID-19 episode

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Ávila‐Nieto, C., de la Concepción, M. L. R., Tarrés-Freixas, F., Izquierdo‐Useros, N., Paredes, R., Mateu, L., et al. (2021) · Topics in antiviral medicine · Cited by 1 · see citing works

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100126 · Cited by 197 · see citing works

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patientsPreprint

Chansaenroj, J., Yorsaeng, R., Wanlapakorn, N., Chirathaworn, C., Sudhinaraset, N., Sripram, M., Chalongviriyalert, P., Jirajariyavej, S., Kiatpanabhikul, P., Saiyarin, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1073046/v1 · Cited by 3 · see citing works

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Ávila‐Nieto, C., de la Concepción, M. L. R., Tarrés-Freixas, F., Pérez-Yanes, S., Rovirosa, C., Ainsua‐Enrich, E., et al. (2021) · Med · doi:10.1016/j.medj.2021.01.005 · Cited by 102 · see citing works